Snipr Biome adjusts its strategy - shifts focus towards gene therapy

There are fundamental market flaws holding back the development of new antibiotics, acknowledges Snipr Biome CEO Christian Grøndahl, as the company pivots to gene technology.

Christian Grøndahl, co-founder and CEO of Snipr Biome | Photo: Snipr Biome/pr

by albert rønning-andersson, translated by daniel pedersen

It’s not lightly that Chief Executive Officer of Snipr Biome Christian Grøndahl decides to change the direction of the CRISPR company.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Snipr Biome shows proof of principle in phase I trial of lead asset
For subscribers
Snipr secures important US patent
For subscribers
Snipr Biome takes aim at antibiotic resistant bacteria in phase I trial
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Pharma & biotech

Investment bank: Novo Nordisk's patent victory is a small victory as price negotiations loom

The market’s attention is more focused on public health insurance Medicare’s new price negotiations under the so-called Inflation Reduction Act.

For subscribers

Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

For subscribers

Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Photo: Liselotte Plenov / Fotorummet / Pr

Pharma & biotech

Fujifilm expands management with former Leo executive

For subscribers

Photo: Andrew Kelly/Reuters/Ritzau Scanpix

Pharma & biotech

Low share price may knock Galecto off the stock exchange

For subscribers

Photo: Mike Segar/Reuters/Ritzau Scanpix

Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug

Photo: Yuriko Nakao/Reuters/Ritzau Scanpix

Medtech

Olympus appoints new chief medical officer

For subscribers

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics
Previous studies have shown that alcohol cravings disappeared when people were treated with GLP-1 agonist exanatide.
For subscribers
Vaccine breakthrough behind mRNA shots wins Nobel Prize
The two scientists will share the 11 million-krona ( USD 1 million) award, the Nobel Assembly at the Karolinska Institutet in Stockholm said in a statement Monday.
For subscribers
WS Audiology hires new chief technology officer from car manufacturer
He succeeds chief research & development officer Stefan Menzl, who is stepping down after six years.
For subscribers
Novo Nordisk files lawsuit against US authorities ahead of price negotiation
The litigation is the latest in a long line of industry lawsuits related to price negotiations.
For subscribers
FDA rejects atopic dermatitis drug lebrikizumab
Eli Lilly had expected a launch this year.
For subscribers
FDA updates Novo Nordisk's Ozempic drug label with side effect alert
The diabetes drug might cause a potentially fatal intestinal blockage, the authorities warn.
For subscribers

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers

Pharma & biotech